Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan-McDermid Syndrome in Children and Adolescents
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Neuren Pharmaceuticals Limited. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Neuren Pharmaceuticals Limited a question about this update.